VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, VBI’s President and CEO, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety and tolerability of VBI’s vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present updates on two of its programs at the World Vaccine Congress on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) and SciVac Ltd. (“SciVac”), a wholly owned subsidiary of VBI, are pleased to announce the appointment of Avi Mazaltov as the Global Head of Manufacturing and General Manager of the SciVac manufacturing...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today that the Biologics and Genetic Therapies Directorate ("BGTD") of Health Canada expressed its general support and acceptance of the company’s development path for its Sci-B-Vac™ vaccine, a prophylactic vaccine against...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today the receipt of positive Scientific Advice from the Committee for Medicinal Products for Human Use ("CHMP") of the European Medical Agency ("EMA") regarding the company’s development path for its Sci-B-Vac™...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”), a clinical-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines, today announced that it has raised $23.6 million in concurrent equity and debt financing transactions with Perceptive Advisors. Under the terms of...
Read More
98.8% of Patients Seroprotected at Two Months Following Second Dose of Sci-B-Vac™ VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac™, VBI’s licensed third-generation hepatitis B vaccine,...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the Keystone Symposia on Translational Vaccinology for Global Health on Thursday, October 27, 2016 at 7:00 PM BST (2:00 PM ET). The event is being held at...
Read More